natgillin/translations-raw huggingface dataset:
A powder formulation to be administered using a medium- or a high-resistance multidose dry powder inhaler device, said formulation comprising an interactive ordered mixture prepared by blending micronized crystalline particles consisting of formoterol fumarate dihydrate as active ingredient, having a nominal dose delivered after each actuation of said inhaler equal to or lower than 4 µg, with particles of a physiologically acceptable excipient having a mass median diameter (MMD) higher than 90 micron, the particles of said active ingredient fulfilling the following conditions: 
Praškasta formulacija za davanje u srednje- ili visokorezistentnom inhalatoru za suhi prašak za višestruke doze, rečena formulacija sadrži interaktivno poredanu smjesu pripravljenu miješanjem mikroniziranih kristaliničnih čestica koje se sastoje od formoterol-fumarat dihidrata kao aktivne tvari, koja se isporučuje u nominalnoj dozi jednakoj ili nižoj od 4 µg nakon svakog pokretanja rečenog inhalatora, s česticama fiziološki prihvatljivog ekscipijensa srednjeg masenog promjera (MMD) većeg od 90 mikrona, čestice rečene aktivne tvari zadovoljavaju sljedeće uvjete:
The method of claim 18 further comprising jacketing the metal tube and tear cord with polyethylene, ethylene chlorotrifluoroerthlyene, a thermoplastic elastomer cross linking ethylene propylene diene monomer rubber and polypropylene, perfluoroalkoxy, polyvinylidene fluoride or fluorinated ethylene propylene. 
19. Postupak u skladu s patentnim zahtjevom 17, naznačen time što dodatno sadrži oblaganje metalne cijevi 1 žice za kidanje polietilenom, etilen-klortrifluoretilenom, termoplastičnim elastomernim umreženim etilen-propilen-dien-monomer-kaučukom i polipropilenom, perfluoralkoksi, poliviniliden-fluoridom ili fluoriranim etilen-propilenom.
Ring A is unsubstituted or is substituted with ethyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof. 
KE Ni gdje Prsten A je nesupstituiran ili je supstituiran sa etil; ili na njihove farmaceutski prihvatljive soli, solvate ili hidrate.
a service machinery space 22 comprising: 
- > prostor 22 za strojeve za posluživanje koji sadržava:
The vessels were heated to 95 °C and stirred for 20 h. 
Reakcijske posude su zagrijavane na 95" C i miješane tijekom 20 sati.
A compound selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine:
The invention also pertains to a method of treatment comprising administering to a male in need of androgen supplementation or testosterone replacement a therapeutically effective amount of a compound according to the invention, optionally in combination with an androgen known in the art, or a progestagen known in the art. 
Ovaj izum također se odnosi na postupak liječenja koji se sastoji u primjeni na muškarcu kojem je potrebna dopuna androgena ili testosteronska zamjena terapijski djelotvorne količina spoja prema ovom izumu, izborno u kombinaciji s androgenom poznatim u struci, ili progestagenom poznatim u struci.
A method for treatment and/or prophylaxis of a cardiovascular disorder comprising administering an effective amount of a compound of the formula (I) 
12. Postupak za proizvodnju spojeva formule (I), naznačen time da [A] spoj s formulom (II)
In a separate vessel, 260 mL of IPAc and 250 mL of water were mixed and cooled to 0 °C. The reaction slurry was charged to the quench keeping the internal temperature below 10 °C. After the addition, the mixture was agitated vigorously for 30 min, the temperature was increased to room temperature and the aqueous layer was cut. 
U odvojenoj posudi, 260 mL IPAc i 250 mL vode su miješani i ohlađeni do 0*C. Reakcijska smjesa je napunjena do gašenja, da se održi interna temperatura ispod 10*C. Nakon dodavanja, smjesa je jako tresena tijekom 30 min, temperatura je povećana do sobne i vodeni sloj izdvojen.
A similar convention is adopted for the other groups listed above such as (1-4C)alkoxy, (2-4C)alkenyl, (2-4C)alkynyl and (2-4C)alkanoyl. 
Slična konvencija prihvaćena je i za sve druge skupine navedene u gornjem tekstu, poput (1-4C)alkoksi, (2-4C)alkenil, (2-4C)alkinil i (2-4C)alkanoila.
The engine of 10 wherein substantially at least 15 % of the total combustion event occurs prior to the crossover valve closing. An engine comprising: 
Postupak opisan patentnim zahtjevom 16, naznačen time što je dodatno uključeno da se: prijelazni ventil (150) zatvara nakon najmanje 15% ukupnog izgaranja plinova.
Pharmaceutical composition made of microparticles for the slow release of an LHRH agonist at least during a period covering the 6th month after injection of said composition, said composition comprising a mixture of a first formulation of microparticles and a second formulation of microparticles, wherein 
Farmaceutski pripravak pripremljen od mikročestica za sporo oslobađanje LHRH agonista triptorelina, naznačeno time što taj pripravak sadrži prvu skupinu mikročestica i drugu skupinu mikročestica, gdje
The peptide of claim 2 or 3, wherein the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 100, 80, or 101 is substituted with phenylalanine, leucine, isoleucine, tryptophan, or methionine. 
Peptid u skladu s patentnim zahtjevom 2 ili 3, naznačen time što je C-terminalna aminokiselina u aminokiselinskom slijedu SEQ ID NO: 194, 174, 178 ili 186 zamijenjena fenilalaninom, leucinom, izoleucinom, triptofanom ili metioninom.
Additional preferred emulsifiers that may be employed include Sorbitan Triisostearate available under the trade name Crill 6 from Croda Oleochemicals, and Polyglyceryl-3 Distearate available under the trade name Cremophor GS 32 from BASF. 
Dodatni poželjni emulgatori koji se mogu upotrijebiti uključuju sorbitan triizostearat, dostupan pod trgovačkim nazivom Crill 6 od Croda Oleochemicals, i poligliceril-3 distearat dostupan pod trgovačkim nazivom Cremophor GS 32 od BASF.
in an amount front about 10% to about 12% by weight and the formulation further comprises: 
(a) u količini od 10% do 12% po masi i formulacija dodatno obuhvaća:
At least 5 % in weight of tin tetrachloride anhydrous 
Najmanje masenih 5 % bezvodnih kositar tetraklorida
The container according to claim 1, wherein the carrier (5) is configured as an open-work frame. 
Spremnik u skladu s patentnim zahtjevom 1, naznačen time što nosač (5) je konstruiran kao otvoreni okvir.
The method of claim 24, wherein the recombinant eukaryotic host cell is a human cell. 
Metoda sukladno patentnom zahtjevu 10, naznačeno time da rekombinantna stanica domaćin je humana stanica.
the length of L3 is at least twice the length of L1;and the linkers provide sufficient mobility for pairing of VL1 and VH1, and for pairing of VL2 and VH2, and wherein the first and second polypeptides form a cross-over light chain-heavy chain pair. 
L, je duljine 1 do 3 ostatka amino kiseline; i pri čemu prvi i drugi polipeptidi tvore prijelazni par laki lanac-teški lanac. Protutijelu sličan vezivni protein prema bilo kojem zahtjevu 1 ili 2, pri čemu:
A peptide as claimed in claim 10, for use in treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated of food intake. 
Peptid sukladno patentnim zahtjevima 1 do 8, naznačen time, da se koristi za liječenje dijabetesa (tip I 1 /1li tip Il), višak tjelesne težine, prekomjerne konzumacije hrane, metaboličkog sindroma, reumatoidnog artritisa, bezalkoholna bolest masne jetre, osteoporoze, ili osteoartritisa 1 u slučajevima lošije razine glukoze u krvi, lošijih reguliran odgovor na testove tolerancije glukoze, ili slabo reguliran unos hrane.
Headset apparatus according to any preceding claim in which an aforesaid reciprocal connection means is an aperture through which an aforesaid headwear connection means is shaped to extend when the attachment means is connected to the earshell. 
Slušalice prema bilo kojem od prethodnih zahtjeva, naznačene time, da je navedeni recipročni spojni uređaj jedna rupa kroz koju se proteže navedeni naglavni spojni uređaj oblikovan u tu svrhu, kada je priključni uređaj spojen na školjku za uho.
Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc. 
Neki oblici kationskih soli obuhvaćaju soli amonija, aluminija, benzatina, bizmuta, kalcija, holina, dietilamina, dietanolamina, litija, magnezija, meglumina, 4-fenilcikloheksilamina, piperazina, kalija, natrija, trometamina i cinka.
According to one aspect of the present invention there is provided a method of making a garment material, comprising: providing a substrate, which may be formed of yarn and may have interstices through it; applying to the substrate a polymeric material and fibres; and coagulating at least some of the polymeric material onto the substrate to form a composite layer of the polymeric material and fibres. 
Postupak za izradu materijala za odjevni predmet, obuhvaća: osiguravanje supstrata koji se sastoji od pređe i ima međuprostorima kroz nju; nanošenje na podlogu polimernog materijala s vlaknima u njemu suspendiranim, pri čemu vlakna imaju duljinu u rasponu od 0,01 mm do 0,04 mm; koagulirajući barem neki od polimernih materijala na podlogu kako bi se stvorio kompozitni sloj polimernog materijala i vlakana.
Omeprazole (1300 g 3.77 mol) was added under vigorous mechanic stirring to a mixture of tetrahydrofuran (131) and 50% aqueous NaOH (296 g, 3.7 mol) and stirring was then continued for 45 min. 
Omeprazol (1300 g, 3,77 mola) je dodan uz snažno mehaničko miješanje u smjesu tetrahidrofurana (13 1) i 50 % vodene otopine NaOH (296 g, 3,7 mola) i miješanje je nastavljeno 45 min.
The method according to claim 1, characterized by that sodium salt of saturated or unsaturated fatty acid is used as alkaline salt of a saturated or unsaturated organic acid with long carbon chain. 
Metoda temeljem zahtjeva 1, naznačena time što se natrijeva sol zasićene 1li nezasićene masne kiseline koristi kao alkalna sol zasićene ili nezasićene organske kiseline sa dugim ugljikovim lancem.
An ester of a compound according to claim 6, which has an ester group corresponding to R1 which is -NHC(=O)COOR, wherein the ester group corresponding to said "R" is NH2. 
22. Fster spoja prema zahtjevu 6, naznačen time, da ima estersku skupinu koja je odgovarajuća za R' koji je -
The word 'comprising' is used in the sense of 'including' rather than in to mean 'consisting of'. A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at pH 6.5 or above, and wherein the inner layer comprises a third polymeric material which is soluble in intestinal fluid, said third polymeric being a polycarboxylic acid polymer that is at least partially neutralised, wherein at least 10% of the carboxylic acid groups of the polycarboxylic acid polymer are in the form of carboxylate anions. 
Postupak proizvodnje formulacije lijeka s odloženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo sukladno patentnom zahtjevu 1, naznačeno time, da navedeni postupak obuhvaća: formiranje jezgre koje sadrži lijek; premazivanje te jezgre pomoću pripravka za oblaganje koji sadrži treći polimerni materijal koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, u sustavu otapala da se formira unutrašnja obložena jezgra; i premazivanje unutarnje obložene jezgre s vanjskim premaznim pripravkom koji sadrži prvi polimerni materijal koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH od pH 6 ili iznad u sustavu otapala, da se dobije vanjska obložena jezgra; naznačeno time, da je taj treći polimerni materijal je neionski polimer, i navedeni unutarnji pripravak za oblaganje sadrži najmanje jedan aditiv odabran iz puferskog sredstva i baze.
The antibody or antibody fragment of claim 1 for use in therapy or the antibody or antibody fragment of claim 2 for use in the treatment of cancer, wherein said antibody or antibody fragment is attached to a radioisotope, a metal chelator, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound. 
Protutijelo ili fragment prema zahtjevu 7 ili 8, naznačeno time da je protutijelo spojeno na skupinu koja je odabrana od: enzima, toksina, terapijskog sredstva, kemoterapijskog sredstva, ili oznake koja se može detektirati; te pri čemu oznaka koja se može detektirati je radioizotop, kelator metala, enzim, fluorescentni spoj, bioluminescentni spoj ili kemiluminescentni spoj.
The composition according to claim 20, wherein the compound of general formula I is polyoxypropylene-15-stearyl ether, polyoxypropylene-11-stearyl ether, polyoxypropylene-14-butyl ether, polyoxypropylene-10-cetyl ether or polyoxypropylene-3-myristyl ether. 
Kompozicija prema zahtjevu 6, pri čemu je spoj opće formule I polioksipropilen-15-stearil eter, polioksipropilen-11-stearil eter, polioksipropilen-14-butil eter, polioksipropilen-10-cetil eter ili polioksipropilen-3-miristil eter.
A process for the preparation of the compounds of Formula I according to claim 1 comprising reacting a compound of Formula II: in which L is a leaving group selected from Cl, Br, I, OSO2CF3, and A, B, R1 and R2 are as defined in Claim 1; with a compound of Formula III: either as the free base or an addition salt hereof; wherein Q, R3, R4, R5, R6 and R7 are as defined in Claim 1; either neat, or in an inert solvent or mixture of solvents, at a temperature between 0 to about 200 °C, optionally in the presence of a base, optionally in the presence of a palladium catalyst, followed by work-up and isolation of the product of Formula I, either as its free base or as an acid addition salt hereof. 
[image] ili u obliku slobodne baze ili njezine adicijske soli; gdje Q, R3, R4, R5, R6 i R7 su kako je definirano u zahtjevu 1; ili čisto ili u inertnom otapalu ili smjesi otapala, pri temperaturi između 0 do oko, po izboru u prisutnosti baze, po izboru paladij katalizatora, nakon čega slijedi dorada i izolacija proizvoda Formule I, ili u obliku slobodne baze ili njezine kisele adicijske soli.
at least one epoxy resin, and 
(A) najmanje jednu epoksi smolu, 1
According to another aspect of the above embodiment, a method is provided wherein the water miscible organic solvent is methanol. 
Postupak prema zahtjevu 9, naznačen time da organsko otapalo koje se miješa s vodom je metanol.
introducing into said auxotrophy cured prokaryotic cell one or more nucleic acids encoding the polypeptide; and cultivating the auxotrophy cured prokaryotic cell comprising one or more nucleic acids encoding the polypeptide in a chemically defined minimal growth medium and recovering the polypeptide from the prokaryotic cell or the periplasm of the prokaryotic cell or from the medium. 
kultiviranja prokariotske stanice kojoj je uklonjen auksotrof, a koja se sastoji od jedne ili više nukleinskih kiselina koje kodiraju polipeptid u kemijski definiranom mediju za minimalni rast te oporavka polipeptida iz prokariotske stanice ili periplazme prokariotske stanice ili iz medija, pri čemu je titar produkta kada se koristi soj prokariotskih stanica kojima je uklonjen auksotrof viši od titra proizvoda koji se može dobiti uz pomoć odgovarajućeg divljeg soja prototrofa.
An ORC apparatus for generation of energy by organic Rankine cycle, comprising: 
PATENTNI ZAHTJEVI ORC uređaj za dobivanje električne energije organskim Rankineovim ciklusom, koji sadrži:
The compound or salt of claim 10 for use wherein said disease is an autoimmune disease. 
Spoj ili sol prema zahtjevu 48 naznačen time da navedena bolest je autoimuna bolest.
The dressing for a wound of claim 1, wherein the compound that contains hydrophobic groups is selected from the group consisting of dialkyl carbamoyl chloride (DACC) and an alkyl ketene dimer (AKD). 
Zavoj za ranu prema zahtjevu 1, naznačen time da je spoj koji sadrži hidrofobne skupine odabran je iz skupine koja se sastoji od dialkil karbamoil klorida (DACC) i alkil keten dimera (AKD).
For example, dilute samples are difficult to purify by this technique. 
Primjerice, razrijeđene je uzorke teško pročistiti ovom tehnikom.
A pharmaceutical composition comprising a therapeutically effective amount of an antibody or fragment thereof according to any one of the claims 1 to 6 or 9 to 11 together with a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time što sadrži terapijski djelotvornu količinu protutijela, ili njegovog fragmenta, u skladu s patentnim zahtjevom 1, uz farmaceutski prihvatljiv nosač.
Fig. 2 schematically the control of implemented in such a device. 
SI. 2 je shema kontrole upotrijebljene u takvoj napravi.
comparing the changes in the detectable signal measured in (iii) for each specific probe. 
(iv) uspoređivanja promjena u detektabilnom signalu izmjerenom u koraku (iii) za svaku specifičnu sondu.
Het is a monocyclic heterocycle selected from the group of N -phenoxypiperidinyl, piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, hydroxy, alkyl or alkyloxy; 
Het je monociklički heterocikal koji je odabran iz skupine koja sadrži N-fenoksipiperidinil, piperidinil, pirolil, pirazolil, imidazolil, furanil, tienil, oksazolil, izoksazolil, tiazolil, izotiazolil, piridinil, pirimidinil, pirazinil i piridazinil; ili biciklički heterocikal koji je odabran iz skupine koja sadrži kinolinil, kinoksalinil, indolil, benzimidazolil, benzoksazolil, benzizoksazolil, benzotiazolil, benzizotiazolil, benzofuranil, benzotienil, 2,3-dihidrobenzo[1,4]dioksinil ili benzo[1,3]dioksolil; svaki monociklički ili biciklički heterocikal može proizvoljno biti supstituiran na atomu ugljika sa 1, 2 ili 3 supstituenta, a svaki supstituent je neovisno odabran iz skupine koja sadrži halo, hidroksi, alkil ili alkiloksi;
The jack system of claim 1, wherein each of the first extremities comprises a protuberant formation configured to bear against and prop the respective arms against an outer surface of the fixed support structure. 
Sustav dizalica (10, 100) sukladno zahtjevu 2, naznačen time da svaki od prvih ekstremiteta (22, 122) sadrži formaciju izbočenja konfiguriranu tako da nosi i učvršćuje odgovarajuće krakove (20,120) na vanjsku površinu fiksne potporne strukture (16,116).
A method according to claim 14, wherein the mineral fibers and binder together make up at least 96%, preferably at least 98% and more preferably substantially all of the total weight of starting materials. 
Postupak sukladno patentnom zahtjevu 16, pri čemu ta mineralna vlakna i vezivno sredstvo zajedno čine najmanje 96%, preporučljivo najmanj 98% 1 još preporučljivije sve od ukupne težine početnih materijala.
A transport unit according to any one of the previous claims, wherein the mineral wool plate package comprises at least four, preferably at least six, more preferably at least eight, mineral wool plates of substantially equal size stacked upon each other such as to form substantially plane side surfaces extending in a width and a height of the mineral wool plate package as well as substantially plane front and back surfaces extending in a length and a height of the mineral wool plate package, the side surfaces extending at right angles to the front and back surfaces. 
Transportna jednica sukladno bilo kojem od prethodnih zahtjeva, pri čemu pakiranje ploča mineralne vune (1) obuhvaća barem četiri, poželjno barem šest, najbolje barem osam, ploča mineralne vune (2) supstancijalno jednakih veličina složenih jedne na drugu tako da formiraju supstancijalno ravne bočne površine koje se pružaju u širini i visini pakiranja ploča mineralne vune (1) kao i supstancijalno ravne prednje i stražnje površine koje se pružaju u duljini i visini pakiranja ploča mineralne vune (1), bočne površine pružaju se pod pravim kutevima prema prednjim i stražnjim površinama.
Container assembly (300) according to any one of the preceding claims, wherein the container assembly (300) comprises a tracking device. 
Sklop (300) posude prema bilo kojem od prethodnih Zahtjeva, gdje sklop (300) posude sadrži uređaj za praćenje.
The concentration range of rat LH standard is 0.001-10 ng/ml, for optimal accuracy measurements of serum LH serum samples were diluted 8-times with assay buffer (J. I. van Casteren et al., Biol. 
Raspon koncentracija štakorskog LH standarda je 0,001-10 ng/ml, a za optimalno točna mjerenja LH u serumu uzorci seruma su razrjeđivani 8 x puferom za ispitivanje (J.I. van Casteren i dr.: Biol.
an HVR-H3 comprising the amino acid sequence of SEQ ID NO:16; and an HC-FR1 comprising the amino acid sequence of SEQ ID NO:25; and a light chain (LC) comprising: 
(3) HVR-H3 koji sadrži aminokiselinsku sekvencu od SEQ ID NO: 16; 1 (4) HC-FRI koji sadrži aminokiselinsku sekvencu od SEQ ID NO:25; i ima slabi lanac (LC) koji obuhvaća:
A process according to claim 2, characterized in that the fixing of the half shells (1, 1') occurs by means of riveting/punching with an automatic mechanical system, by means of the preliminary formation of holes (6) on the half shells (1, 1') via the insertion of fixing rivets. 
Postupak prema zahtjevu 2, naznačen time što se fiksiranje polu-okvira (1, 1) obavlja pomoću zakivanja/probijanja pomoću automatskog mehaničkog sustava, umetanjem zakovica za fiksiranje kroz prethodno probijene rupe (6) na polu-okvirima (1, 1").
The use of any one of paragraphs 35-40, wherein the chronic kidney disease or proteinuria is caused by diabetic nephropathy or high blood pressure. 
7. = Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je kronična bubrežna bolest ili proteinurija posljedica dijabetične nefropatije ili visokog krvnog tlaka.
an amino acid sequence having at least 90% homology to amino acid residues 20 to 139 of SEQ ID NO: 30; and further comprising 
aminokiselinska sekvenca koja ima najmanje 90% homologije sa aminokiselinskim ostacima 20 do 139 iz sekv. id. br.: 30; i dalje sadrži
Only with great difficulty could the gel be pressed through a 0.9 mm injection cannula. 
Gel se moglo samo vrlo teško sprešati injekcijskom kanilom od 0,9 mm.
manufacturing a catheter tube (10) with longitudinal protrusions (14) facing radially outwards, and 
izradu reverzibilne kateterske cijevi (10) sa uzdužnim izbočenjima (14) radijalno usmjerenim prema van, i -
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) biksafen.
soluble in water; and/or 
(1) topljiva u vodi; i/ili